An experimental model of diabetes and cancer in rats

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 889-894

  Cocca, C ^a   Martin, G ^a   Rivera, E ^a   Davio, C ^a   Cricco, G ^a   Lemos, B ^a   Fitzsimons, C ^a   Gutierrez, A ^a   Levin, E ^a   Levin, R ^b   Croci, M ^c   Bergoc, R M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Centro de Investigaciones Oncológicas   (Argentina)

^c Hospital General De Agudos Teodoro Alvarez   (Argentina)

Author keywords

Diabetes; Mammary tumours; N nitroso N methylurea; Rats; Streptozotocin; Tamoxifen

Indexed keywords

GLUCOSE; INSULIN; METHYLNITROSOUREA; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; STREPTOZOCIN; TAMOXIFEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGRESSION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT PERIOD; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL DIVISION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FEMALE; INSULIN; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; RATS; STREPTOZOCIN; TAMOXIFEN;

EID: 0032078280     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10077-6     Document Type: Article

References (41)

1. Cullen KJ, Yee D, Rosen N. Insulin like growth factors in human malignancy. Cancer Invest 1991, 9, 443-454.
2. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995, 49, 415-421.
3. Yee D. Insulin-like growth factors system as a target in breast cancer. Breast Cancer Res Treat 1994, 32, 415-421.
4. Kamysheva EP, Abelevich IG, Andriukhina G, et al. Diabetes mellitus and cancer. Ross Med Zh 1992, 2, 8-11.
5. Levin E, Levin RW. Better evolution of breast cancer in type II diabetic patients under tamoxifen and hypoglycemic sulfonylureas treatment. Abstracts V Int Congress Hormones & Cancer, Quebec, 1995.
6. Rhomberg W. Metastasierendes Mammakarzinom und Diabetes mellitus-eine prognostisch günstige Krankheitskombination. Dtsch med Wschr 1975, 100, 2422-2427.
7. Guerra FK, Eijan AM, Puricelli L, et al. Varying pattern of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer 1996, 65, 812-820.
8. Le Roith D, Baserga R, Helman L, Roberts CT Jr. Insulinlike growth factors and cancer. Ann Intern Med 1995, 122(1), 5459.
9. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995, 55, 249-252.
10. Giustina A, Ruggeri G, Bodini C, et al. Insulin-like growth factor I and growth hormone levels in patients with type I diabetes mellitus. Int Symp Biotechnol Growth Factors. In Lefant C, Paoletti R, Albertini A, eds. Growth Factors on the Vascular and Nervous Systems. Basle, Karger, 1992, 115-122.
11. Häring A, Kelleler M, Mosthaf L. Modulation of insulin signaling in non-insulin dependent diabetes: significance of altered receptor isoforms patterns and mechanisms of glucose-induced receptor modulation. Horm Res 1994, 41, 87-92.
12. Strasser-Vogel B, Blum WF, Past R, et al. Insulin-like growth factor (IGF) I and II-binding proteins-1, -2 and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. J Clin Endocrinol Metab 1996, 80(4), 1207-1213.
13. Pollack MN, Huynh HT, Pratt Lefrevre S. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 1992, 22, 91-100.
14. Friedl A, Jordan VC, Pollak M. Suppression of serum insulinlike growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993, 29A, 1368-1372.
15. Lonning PE, Hall K, Povoa A, et al. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein-1 in breast cancer patients. Cancer Res 1992, 52, 4719-4723.
16. Gibson JM, Westwood M, Crosby SR, et al. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996, 80(4), 1369-1375.
17. Hall K, Johansson BL, Povoa G, Thalme B. Serum levels of insulin-like (IGFs) I and II and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion. Int Med 1995, 225, 270-278.
18. Cohen ND, Hilf R. Influence of insulin on growth and metabolism of 7,12-dimethylbenzo(a)antracene (DMBA)-induced mammary tumors. Cancer Res 1974, 34, 3245-3252.
19. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenzo(a)antracene (DMBA)-induced mammary carcinoma in rats subjected to alloxan diabetes. Cancer Res 1972, 32, 226-232.
20. Rerup CC. Drugs producing diabetes through damage of the insulin secretion cells. PharmacolRev 1970, 22, 485-518.
21. Weir GC, Clare ET, Zmachinski CJ, Bonner-Weir S. Islet secretion in a new experimental model for non-insulin-dependent diabetes. Diabetes 1981, 30, 590-595.
22. Levy J, Gavin J, Fausto A, Gingerich R, Avioli L. Impaired insulin action in rats with non-insulin-dependent diabetes. Diabetes 1984, 35, 901-906.
23. Maloff BL, Boyd BK. Physiologic and cellular insulin action in a glucose-intolerant model of type 2 (non-insulin-dependent) diabetes in rat. Diabetologia 1986, 29, 295-300.
24. Kergoat M, Portha B. In vivo hepatic and peripheral insulin sensitivity in rats non-insulin-dependent diabetes induced by streptozocin. Diabetes 1985, 34, 1120-1125.
25. Rivera E, Melito G, Davio G, et al. Histopathology and influence of the estral cycle on NMU induced tumors in rats. Cancer Lett 1994, 86, 223-228.
26. Martin G, Melito G, Rivera E, et al. Receptor characterization in ip NMU-induced tumors. Cancer Lett 1996, 101, 1-8.
27. Martin G, Davio D, Rivera E, et al. Hormone dependence of mammary tumors induced in rats by intraperitoneal NMU injection. Cancer Invest 1997, 15(1), 8-17.
28. Agresti A. Categorical Data Analysis. New York, John Wiley, 1990.
29. Connover W. Practical Non-parametric Statistic. New York, John Wiley, 1990.
30. Martin G, Melito G, Rivera E, et al. Effect of tamoxifen in i.p. NMU-induced tumors. Cancer Lett 1996, 100, 227-234.
31. Tesone M, Calvo J, Barañao J, Charreau E. Diabetes and male reproductive functions. In Andrology. Male Fertility and Sterility. New York, Academic Press, 1986, 85-98.
32. Tesone M, Ladenheim R, Cheb-Tarrab R, et al. Comparison between bioactive and immunoactive luteinizing hormone (LH) in ovariectomized streptozotocin-induced diabetic rats: response to LH-releasing. Proc Soc Exp Biol Med 1983, 174, 123-130.
33. Jordan VC, Dowse LJ. Tamoxifen as an anti-tumor agent I: effect on oestrogen binding. J Endocr 1976, 68, 297-303.
34. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994, 31, 41-52.
35. Haran EF, Maretzek AF, Goldemberg I, Horowitz A, Degani H. Tamoxifen enhances cell death in implanted MCF-7 breast cancer by inhibiting endothelium growth. Cancer Res 1994, 54, 5511-5514.
36. Pollak M, Costantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990, 82, 1693-1697.
37. Lonning PE, Lien EA, Lundgren S, Kvinnsland S. Clinical pharmacokinetics on endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992b, 22, 327-358.
38. Helle SI, Holly JMP, Tally M, Hall K, Stappen J van der, Lonning PE. Influence of treatment with tamoxifen and change in tumor burden of the IGF-system in breast cancer patients. Int J Cancer 1996, 69, 335-339.
39. De Cupis A, Noonan D, Pirani P, Ferrera A, Clerico L, Favoni R. Comparison between novel steroid-like and conventional non-steroidal antiestrogens in inhibiting oestradiol and IGF-Iinduced proliferation of human breast cancer-derived cells. Am J Physiol 1991, 260, 561-567.
40. Kaleko M, Rutter W, Miller D. Overexpression of the human insulin like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990, 10, 464-473.
41. Werner H, Shen-Orr Z, Stannard B, Burgera B, Roberts Ch, LeRoith D Jr. Experimental diabetes increases insulin-like growth factor I and II receptor concentration and gene expression in kidney. Diabetes 1990, 39, 1490-1497.